Table 1.
Enrichment for deletions and amplifications for BRCA1 and not BECN1 in human cancers. Only statistically significant enrichments have their Bonferroni corrected p-values shown.
| Cancer | Number of tumor/normal pairs |
Average CNA per tumor | BECN1 alone | BRCA1 alone | Both BECN1 and BRCA1 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deletion | Amplification | Deletion | Amplification | p-value | Deletion | Amplification | p-value | Deletion | Amplification | p-value | ||
| Acute Myeloid Leukemia | 196 | 146 | 146 | 1 | 1 | 0 | 0 | 4 | 1 | |||
| Bladder Urothelial Carcinoma | 184 | 99 | 106 | 0 | 0 | 0 | 0 | 3 | 25 | 0.01442 | ||
| Brain Lower Grade Glioma | 269 | 34 | 32 | 1 | 0 | 0 | 0 | 2 | 3 | |||
| Breast invasive carcinoma | 999 | 85 | 111 | 3 | 7 | 24 | 4 | 2.42E-03 | 149 | 86 | 4.00E-03 | |
| Cervical squamous cell carcinoma and endocervical adenocarcinoma |
155 | 52 | 61 | 1 | 0 | 2 | 0 | 6 | 10 | |||
| Colon adenocarcinoma | 460 | 70 | 71 | 3 | 2 | 7 | 1 | 25 | 50 | |||
| Glioblastoma multiforme 1 | 434 | 29 | 25 | 1 | 0 | 1 | 1 | 17 | 16 | |||
| Glioblastoma multiforme 2 | 237 | 30 | 27 | 2 | 1 | 1 | 2 | 14 | 9 | |||
| Glioblastoma multiforme 3 | 170 | 35 | 29 | 0 | 0 | 1 | 0 | 10 | 1 | |||
| Glioblastoma multiforme 4 | 534 | 106 | 109 | 0 | 1 | 3 | 1 | 28 | 20 | |||
| Head and Neck squamous cell carcinoma |
390 | 49 | 55 | 0 | 0 | 1 | 1 | 9 | 20 | |||
| Kidney Chromophobe | 66 | 97 | 75 | 1 | 0 | 1 | 0 | 30 | 0 | 0.00021 | ||
| Kidney renal clear cell carcinoma | 550 | 35 | 44 | 0 | 1 | 2 | 0 | 9 | 4 | |||
| Kidney renal papillary cell carcinoma | 168 | 30 | 49 | 0 | 0 | 0 | 0 | 0 | 63 | 8.36E-07 | ||
| Liver hepatocellular carcinoma | 136 | 52 | 88 | 0 | 2 | 1 | 2 | 3 | 18 | |||
| Lung adenocarcinoma | 505 | 50 | 66 | 0 | 2 | 0 | 2 | 6 | 46 | 0.00698 | ||
| Lung squamous cell carcinoma 1 | 117 | 51 | 50 | 1 | 0 | 0 | 0 | 14 | 10 | |||
| Lung squamous cell carcinoma 2 | 505 | 100 | 109 | 2 | 3 | 7 | 0 | 36 | 44 | |||
| Lymphoid Neoplasm Diffuse Large B-cell Lymphoma |
18 | 49 | 48 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Ovarian serous cystadenocarcinoma 1 | 587 | 105 | 109 | 7 | 2 | 10 | 3 | 299 | 13 | 2.03E-35 | ||
| Ovarian serous cystadenocarcinoma 2 | 97 | 76 | 92 | 2 | 0 | 3 | 0 | 72 | 1 | 1.17E-13 | ||
| Ovarian serous cystadenocarcinoma 3 | 355 | 93 | 121 | 2 | 1 | 3 | 2 | 208 | 13 | 4.05E-31 | ||
| Ovarian serous cystadenocarcinoma 4 | 586 | 253 | 363 | 16 | 4 | 47 | 3 | 2.42E-12 | 252 | 19 | 8.09E-47 | |
| Pancreatic adenocarcinoma | 66 | 29 | 30 | 0 | 0 | 0 | 0 | 2 | 0 | |||
| Prostate adenocarcinoma | 195 | 46 | 29 | 1 | 2 | 1 | 0 | 9 | 0 | |||
| Rectum adenocarcinoma | 167 | 81 | 83 | 0 | 1 | 0 | 0 | 12 | 14 | |||
| Sarcoma | 84 | 71 | 122 | 0 | 1 | 0 | 1 | 4 | 3 | |||
| Skin Cutaneous Melanoma | 338 | 54 | 78 | 0 | 0 | 2 | 2 | 14 | 27 | |||
| Stomach adenocarcinoma | 306 | 44 | 59 | 1 | 1 | 6 | 2 | 12 | 18 | |||
| Thyroid carcinoma | 505 | 15 | 18 | 0 | 0 | 1 | 0 | 0 | 13 | |||
| Uterine Corpus Endometrioid Carcinoma | 505 | 62 | 91 | 3 | 3 | 12 | 2 | 55 | 15 | 1.15E-05 | ||